KURA

Kura Oncology's stock has trended down by 4.46% in the past six months, with a 52-week range between $5.45 and $12.49. Key events impacting the stock include Q4 2025 earnings missing consensus estimates, the FDA approval of KOMZIFTI, promising darlifarnib combination data, participation in healthcare conferences, and a 1-for-35 reverse stock split on October 18, 2024.